+13%

est. 2Y upside i

Healthcare

Rank

#1767

Sector

Healthcare IT

Est. Liquidity

~3Y

Data Quality

Data: Low

The expected upside over 2 years is only ~13% with 50% probability of a 36% loss.

Last updated: July 19, 2026

Bull (20%)+100%

Veradigm brand revitalization and new product partnerships drive multiple expansion to 3x, implying $4.5B exit value. Capped at 100% upside per late-stage constraint.

Base (30%)+36%

Revenue remains flat at ~$1.5B; multiple converges to industry average of 2x, giving exit value of $3.0B, a 36% gain from the $2.2B entry.

Bear (50%)-36%

Intense competition from Epic and Oracle Health compresses multiple to 1x, leading to $1.5B exit. After $100M preference, common equity falls to $1.4B, a 36% loss.

Est. time to liquidity~3.0 years

Preference Stack Risk

low

Funding Intensity

450%

Total preferred stock of $100M represents 4.5% of the $2.2B valuation, posing minimal liquidation preference overhang.

Dilution Risk

low

Company is profitable and part of a larger entity; no near-term capital raise expected.

Secondary Liquidity

limited

As a subsidiary of a private company, employee equity likely has restricted liquidity; secondary sales may be possible only in special tender offers.

View all 86 open roles at Allscripts →

Last updated: July 3, 2026

Questions to Ask at the Interview

Strategic questions based on Allscripts's data — designed to show you've done your homework.

  • 1

    “How will Veradigm compete against Epic and Oracle Health in the EHR market?”

  • 2

    “What is the strategy to reignite growth given the flat revenue trend?”

  • 3

    “How does Constellation Software's ownership affect equity liquidity and future exit possibilities?”

Community

Valuation Sentiment

Our model estimates +13% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.